Peripheral Artery Disease (PAD)

This channel includes news, interventions, and new technology innovations for peripheral artery diease, PAD and critical limb ischemia.

Some of the top technology news from ACC 2021. Top left, the LAAOS III trial showed benefit when surgeons seal off the LAA during other open heart procedures. Bottom left, the ReCor Paradise renal denervation system helped lower blood pressure in patients who did not respond to medication. Top right, for patients with both heart failure and AFib it makes no differences is therapy is focused on controlling the heart rhythm or heart rate. Bottom right, the FLOWER-MI trial found no benefit to FFR-guided PCI.

Feature | ACC | By Dave Fornell, Editor

Key Cardiology Technology Takeaways at ACC 2021

Here are the top 10 takeaways from the late-breaking studies on cardiovascular technologies presented at the 2021 Americ ...

June 08, 2021

Two years ago a study raised concerns that paclitaxel-coated devices may cause increased mortality in peripheral artery disease patients. However, numerous studies now show there is no risk of increased mortality. The most recent study is the SAFE-PAD study presented at ACC.21.

News | Peripheral Artery Disease (PAD)

SAFE-PAD Study Shows No Safety Issues With Paclitaxel-coated Devices In Peripheral Artery Disease

June 7, 2021 — A couple years ago a study showed a mortality safety signal in patients who underwent peripheral artery ...

June 07, 2021

The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization. The findings from the VOYAGER PAD trial were presented at the American College of Cardiology (ACC) 2021 Scientific Session.

News | Peripheral Artery Disease (PAD)

Rivaroxaban Reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

May 17, 2021 — The anticoagulant rivaroxaban (Xarelto), in addition to low-dose aspirin, significantly reduced the ...

May 17, 2021

News | Venous Therapies

FDA Clears Zilver Vena Venous Self-Expanding Stent

February 22, 2021 — The U.S. Food and Drug Administration (FDA) recently cleared the Cook Medical Zilver Vena Venous ...

February 22, 2021

An interventional radiologist consults with a patient in an out patient cath lab at a Modern Vascular clinic. The company is building several out patient clinics to capture a share of the interventional market for peripheral artery disease (PAD) catheter-based therapies.

News | Cardiovascular Business

Modern Vascular Opens New Outpatient Cath Lab to Treat Peripheral Artery Disease

February 3, 2021 — Modern Vascular is a medical group that has 13 outpatient cath lab clinics to treat peripheral artery ...

February 03, 2021

The Pedra Blood Perfusion Index tracks real-time changes in foot tissue perfusion attendant with balloon inflation and deflation during an angioplasty procedure.

News | Peripheral Artery Disease (PAD)

Pedra Tissue Perfusion System Receives FDA Breakthrough Device Designation

January 26, 2021 — Pedra Technology, a privately held company, announced today that the U.S. Food and Drug ...

January 26, 2021

A peripheral artery disease (PAD) patient CT scan showing blockages in the femoral arteries in the legs with collateral flow in the leg on the right.

News | Stents Bioresorbable

First-In-Human Use Reported for Bioresorbable Efemoral Vascular Scaffold System

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

December 16, 2020

The FDA-Cleared XO Score is different. XO Score technology allows users to convert basic angioplasty balloons in the hospital's existing inventory into sophisticated scoring, cutting, and infusion/delivery devices.

News | Peripheral Artery Disease (PAD)

New Angioplasty System Dilates Calcified and Fibrotic Vessels

November 13, 2020 — The new U.S. Food and Drug Administration (FDA) cleared XO Score system was successfully used to ...

November 13, 2020

The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated Balloon, developed for the treatment of patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA) and proximal popliteal artery (PPA).

News | Drug-Eluting Balloons

FDA Clears Boston Scientific Ranger Drug-coated Balloon

November 3, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the Boston Scientific Ranger Drug-coated ...

November 03, 2020

Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip. Acurate neo TAVR valve. #TCTconnect #TCT2020

Feature | TCT | Dave Fornell, Editor

Top 10 Takeaways on Interventional Technologies at TCT 2020

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

October 29, 2020

A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect

Feature | Cath Lab

No Mortality Risk Associated With Paclitaxel-coated Devices Used to Treat Peripheral Artery Disease

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

October 18, 2020

The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the safety and effectiveness of the Medtronic IN.PACT 0.014 drug-coated balloon (DCB) in critical limb ischemia (CLI) subjects with chronic total occlusion (CTO) in the infrapopliteal arteries. The data were presented in the Late-Breaking Clinical Trial Sessions at 2020 Transcatheter Cardiovascular Therapeutics (TCT) Connect virtual symposium of the Cardiovascular Research Foundation (CRF). #TCTconnect #TCT2020

News | Drug-Eluting Balloons

Drug-coated Balloon for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

October 18, 2020

Philips introduced the QuickClear Mechanical Thrombectomy System. It is a simple thrombectomy solution provides physicians with an all-in-one, single-use aspiration catheter and pump system.

News | Thrombectomy Devices

Philips Introduces QuickClear Mechanical Thrombectomy System for Blood Clot Removal

September 25, 2020 — Philips Healthcare launched its QuickClear mechanical thrombectomy system. The compact, single-use ...

September 25, 2020

News | Chronic Total Occlusion (CTO)

FDA Clears TigerEye Image-guided CTO Crossing System

September 14, 2020 — Avinger received U.S. Food and Drug Administration (FDA) 510(k) clearance from the FDA for its ...

September 14, 2020

The U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment (NTAP) for the Boston Scientific Eluvia Drug-Eluting Vascular Stent System as part of the 2021 Inpatient Prospective Payment System (IPPS).

News | Peripheral Artery Disease (PAD)

CMS Grants Additional Reimbursement for Eluvia Vascular Stent

September 4, 2020 — The U.S. Centers for Medicare and Medicaid Services (CMS) granted a New Technology Add-on Payment ...

September 04, 2020